OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
29
Results
Show all
Save search
Copy query
Show results for
Unknown
(29)
Publication Date
Release Date
2023
(10)
2021
(9)
2022
(4)
2020
(2)
2025
(1)
2024
(1)
2012
(1)
2009
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1.
Not available
S-EPMC10296524
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Not available
S-EPMC8362592
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594
|
biostudies-literature
Cite
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
Not available
S-EPMC7953461
|
biostudies-literature
Cite
2023 Canadian Surgery Forum: Sept. 20-23, 2023.
Not available
S-EPMC10718225
|
biostudies-literature
Cite
Simvastatin in Critically Ill Patients with Covid-19.
Not available
S-EPMC10755839
|
biostudies-literature
Cite
Decreased Self-reported Physical Fitness Following SARS-CoV-2 Infection and the Impact of Vaccine Boosters in a Cohort Study.
Not available
S-EPMC10733205
|
biostudies-literature
Cite
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.
Not available
S-EPMC3641846
|
biostudies-literature
Cite
Mortality results from a randomized prostate-cancer screening trial.
Not available
S-EPMC2944770
|
biostudies-literature
Cite
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC10326520
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets